Patents by Inventor Rakesh Kumar Sit
Rakesh Kumar Sit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11813260Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: GrantFiled: May 26, 2023Date of Patent: November 14, 2023Assignee: Recurium IP Holdings, LLCInventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Patent number: 11813259Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: GrantFiled: March 28, 2022Date of Patent: November 14, 2023Assignee: RECURIUM IP HOLDINGS, LLCInventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Publication number: 20230212118Abstract: Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.Type: ApplicationFiled: April 21, 2021Publication date: July 6, 2023Inventors: Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, John Knight, Joseph Robert Pinchman, Aditya Krishnan Unni, Rakesh Kumar Sit, Shuguang Zhu, Chad Daniel Hopkins, Ian Scott
-
Patent number: 11590126Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: GrantFiled: January 8, 2019Date of Patent: February 28, 2023Assignee: Recurium IP Holdings, LLCInventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Publication number: 20220226314Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: ApplicationFiled: March 28, 2022Publication date: July 21, 2022Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Patent number: 11344546Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: GrantFiled: January 8, 2019Date of Patent: May 31, 2022Assignee: Recurium IP Holding, LLCInventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Patent number: 11318134Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: GrantFiled: January 8, 2019Date of Patent: May 3, 2022Assignee: Recurium IP Holdings, LLCInventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Publication number: 20210330651Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: ApplicationFiled: July 6, 2021Publication date: October 28, 2021Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
-
Patent number: 11065233Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: GrantFiled: May 5, 2020Date of Patent: July 20, 2021Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
-
Patent number: 11065234Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: GrantFiled: May 5, 2020Date of Patent: July 20, 2021Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
-
Patent number: 10959989Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: GrantFiled: May 5, 2020Date of Patent: March 30, 2021Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
-
Publication number: 20210009543Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: ApplicationFiled: January 8, 2019Publication date: January 14, 2021Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Publication number: 20200339605Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: ApplicationFiled: January 8, 2019Publication date: October 29, 2020Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Publication number: 20200338071Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: ApplicationFiled: January 8, 2019Publication date: October 29, 2020Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Publication number: 20200268714Abstract: Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.Type: ApplicationFiled: January 6, 2020Publication date: August 27, 2020Inventors: Peter Qinhua Huang, Mehmet Kahraman, Deborah Helen Slee, Kevin Duane Bunker, Chad Daniel Hopkins, Joseph Robert Pinchman, Sunny Abraham, Rakesh Kumar Sit, Daniel Lee Severance
-
Publication number: 20200261428Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: ApplicationFiled: May 5, 2020Publication date: August 20, 2020Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
-
Publication number: 20200261429Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: ApplicationFiled: May 5, 2020Publication date: August 20, 2020Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
-
Publication number: 20200261430Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: ApplicationFiled: May 5, 2020Publication date: August 20, 2020Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
-
Patent number: 10525036Abstract: Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.Type: GrantFiled: March 31, 2016Date of Patent: January 7, 2020Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Mehmet Kahraman, Deborah Helen Slee, Kevin Duane Bunker, Chad Daniel Hopkins, Joseph Robert Pinchman, Sunny Abraham, Rakesh Kumar Sit, Daniel Lee Severance
-
Patent number: 10493060Abstract: Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.Type: GrantFiled: March 15, 2019Date of Patent: December 3, 2019Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Mehmet Kahraman, Deborah Helen Slee, Kevin Duane Bunker, Chad Daniel Hopkins, Joseph Robert Pinchman, Sunny Abraham, Rakesh Kumar Sit, Daniel Lee Severance
